eligibility_summary
Inclusion: Adults ≥18 with histologically confirmed aggressive B‑NHL, life expectancy >3 months, adequate organs (EF ≥50%, ALT/AST ≤2×ULN, CrCl ≥80 mL/min, creatinine <160 mmol/L, SpO2 >91% room air), marrow reserve (Hb ≥90 g/L, Plt ≥70×10^9/L, ANC ≥1.5×10^9/L), informed consent, contraception if applicable. Exclusion: major liver/renal dysfunction, symptomatic heart disease/NYHA ≥2, QTc >500 ms, active HBV/HCV, uncontrolled infection, HIV, other active cancers, need systemic steroids, pregnancy/lactation, refusal of consolidation auto‑HSCT for financial reasons, psychological barriers, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT07059741 tests an integrated sequence for relapsed/refractory aggressive B‑NHL: localized radiotherapy (dose tailored by PET/CT) + reduced‑intensity SEAM (CNS‑uninvolved) or TB (CNS‑involved) conditioning, followed by autologous stem cell transplantation (ASCT) and sequential CAR‑T cells. Interventions and mechanisms: radiotherapy (local ionizing radiation causing DNA double‑strand breaks and immunogenic debulking), SEAM—simustine (nitrosourea alkylating agent), cytarabine (antimetabolite inhibiting DNA polymerase), etoposide (topoisomerase II inhibitor), melphalan (alkylating agent), TB—thiotepa (alkylating agent), busulfan (alkylating agent) for myeloablation. CAR‑T is autologous cellular immunotherapy, engineered T cells target B‑cell antigens to kill malignant B cells. Targets: malignant B lymphocytes, DNA replication/repair pathways (polymerase, topo II), and marrow for conditioning.